Core Insights - Cellectar Biosciences, Inc. will report its financial results for Q1 2025 and provide a corporate update on May 13, 2025, at 8:30 a.m. Eastern Time [1] Company Overview - Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on discovering and developing proprietary drugs for cancer treatment, utilizing its Phospholipid Drug Conjugate™ (PDC) delivery platform to enhance efficacy and safety [3] Product Pipeline - The company's product pipeline includes lead assets such as iopofosine I 131, CLR 225, and CLR 125, targeting various solid tumors and leveraging advanced drug delivery technologies [4] - Iopofosine I 131 is currently in Phase 2b trials for relapsed or refractory multiple myeloma and CNS lymphoma, and is eligible for a Pediatric Review Voucher from the FDA [5] Regulatory Designations - Iopofosine I 131 has received multiple designations from the FDA, including six Orphan Drug, four Rare Pediatric Drug, and two Fast Track designations, as well as two Orphan Drug designations and PRIME designation from the EMA [5]
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025